Companies · Biotechnology

ABS Corp

MINNETONKA · Biotechnology

Diligence memoA one-page analyst read on ABS Corp — recommendation, valuation, rhythm, risks.
$133K
Total raised · real
1
Rounds
Latest step-up
Top 99%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Wed Jul 11 2012 00:00:00 GMT+0000 (Coordinated Universal Time)

ABS Corp looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.37× the median modeled value of Pre-Seed Biotechnology companies in 2010–2012 (132 peers) — value vs value, same stage and era.
Dormant
  • Last raise 14.0 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

ABS Corp is one of 4293 Biotechnology companies tracked from MINNETONKA. By capital raised it ranks in the long tail (ahead of 2% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$2.5M$5.0M$7.5M$10MPre-Seed · 2012-07-11 Raised $133K (real) Modeled valuation $7.3M (est)$133K$7.3MPre-Seed2012

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$133K · 2012

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$7.3M
Base estimate est.
$71K
Conservative case
$82.9M
Upside case
$736K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
6.0 yr
Elapsed time used
14.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
14.0 yr
On record since
2012
First round
1
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$133K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.3× of median
This company$133K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$7.3M
Sector median$64.2M

Raised more than 2% of sector peers (real $). Modeled value above 15% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #120 of 132.

This companyCohort peer
$1.0M$10.0M$100.0M$100K$1.0M$10.0MCapital raised (log)Hygeia Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)Act Biotech Inc · Pre-Seed Raised $2.5M · modeled $55.2M (est)Ikonopedia, LLC · Pre-Seed Raised $2.8M · modeled $55.2M (est)Iquum Inc · Pre-Seed Raised $1.0M · modeled $55.2M (est)Koronis Pharma, Inc. · Pre-Seed Raised $1.3M · modeled $55.2M (est)Olive Medical Corp · Pre-Seed Raised $2.6M · modeled $55.2M (est)Microarrays, Inc. · Pre-Seed Raised $1.0M · modeled $55.2M (est)INTICA Biomedical, Inc. · Pre-Seed Raised $1.6M · modeled $54.9M (est)LightStat, LLC · Pre-Seed Raised $970K · modeled $53.6M (est)Cyto Wave Technologies Inc. · Pre-Seed Raised $965K · modeled $53.3M (est)Curis Inc · Pre-Seed Raised $964K · modeled $53.2M (est)Real Imaging, Ltd. · Pre-Seed Raised $930K · modeled $51.3M (est)ABS Corp (this company) Raised $133K · modeled $7.3M (est)ABS Corp
CompanyStageRaised · realValue · estvs peer med.
Hygeia Therapeutics, Inc.Pre-Seed$1.0M$55.2M2.82×
Act Biotech IncPre-Seed$2.5M$55.2M2.82×
Ikonopedia, LLCPre-Seed$2.8M$55.2M2.82×
Iquum IncPre-Seed$1.0M$55.2M2.82×
Koronis Pharma, Inc.Pre-Seed$1.3M$55.2M2.82×
Olive Medical CorpPre-Seed$2.6M$55.2M2.82×
Microarrays, Inc.Pre-Seed$1.0M$55.2M2.82×
INTICA Biomedical, Inc.Pre-Seed$1.6M$54.9M2.81×
LightStat, LLCPre-Seed$970K$53.6M2.74×
Cyto Wave Technologies Inc.Pre-Seed$965K$53.3M2.72×
Curis IncPre-Seed$964K$53.2M2.72×
Real Imaging, Ltd.Pre-Seed$930K$51.3M2.62×
ABS Corp this companyPre-Seed$133K$7.3M0.37×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$133K2012-07-11$736K$7.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$133K2012-07-11
    • First recorded raise — entered as Pre-Seed.
Intelligence
Modeled next raise
$212K
Modeled next size est.range $138K$339K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Charlie Clarence Mitchell2012-07
Jacques Clarence Stassart2012-07
Jeffrey Clarence Felt2012-07
John Clarence Graves2012-07
Warren Clarence Bielke2012-07
Registry & provenance

ABS Corp is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1558406
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Hemostemix Inc.BiotechnologyPre-Seed$132K$7.3Msame sector · same stage
RiverTown Therapeutics, Inc.BiotechnologyPre-Seed$133K$7.3Msame sector · same stage
Biocurity, Inc.BiotechnologyPre-Seed$135K$7.5Msame sector · same stage
Innate Immunity LlcBiotechnologyPre-Seed$130K$6.5Msame sector · same stage
KinaRX, LLCBiotechnologyPre-Seed$130K$7.2Msame sector · same stage
NeuroGeneCES LLCBiotechnologyPre-Seed$130K$7.2Msame sector · same stage
X-Sight IncBiotechnologyPre-Seed$130K$5.1Msame sector · same stage
Emerald Health Bioceuticals Inc.BiotechnologyPre-Seed$127K$7.0Msame sector · same stage
Frequently asked
How much funding has ABS Corp raised?
ABS Corp has raised approximately $133K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is ABS Corp's estimated valuation?
Provath's modeled valuation for ABS Corp is approximately $7.3M (modeled range $71K–$82.9M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is ABS Corp at?
ABS Corp's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Wed Jul 11.
What does ABS Corp do and where is it based?
ABS Corp operates in the Biotechnology sector, based in MINNETONKA.
Explore related

See where ABS Corp sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at ABS Corp, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.